ArticleOncogenesis2016
Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine.
Article in Oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- Article
- Exosomal microRNA-92b Is a Diagnostic Biomarker in Breast Cancer and Targets Survival-Related MTSS1L to Promote Tumorigenesis.International journal of molecular sciences · 2024Article
- The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Review
- A systematic study of critical miRNAs on cells proliferation and apoptosis by the shortest path.BMC bioinformatics · 2020Article
- Article
- MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A.Cancer cell international · 2020Article
- Developing a 'personalome' for precision medicine: emerging methods that compute interpretable effect sizes from single-subject transcriptomes.Briefings in bioinformatics · 2019Review
- Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.Computers in biology and medicine · 2018Article
- Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.Annals of surgical oncology · 2018Article
- Key Enabling Technologies for Point-of-Care Diagnostics.Sensors (Basel, Switzerland) · 2018Review
- Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer.BMC cancer · 2018Article
- Target-enrichment sequencing for detailed characterization of small RNAs.Nature protocols · 2018Article
- Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.Journal of biomedical science · 2018Review
- Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.BMC genomics · 2018Article
- Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.Molecular cancer · 2017Article
- Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells.Theranostics · 2017Article
- Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have key roles in breast cancer progression, and their expression levels are heterogeneous across individual breast cancer patients. Traditional methods aim to identify differentially expressed miRNAs in populations rather than in individuals and are affected by the expression intensities of miRNAs in different experimental batches or platforms. Thus it is urgent to conduct miRNA differential expression analysis at an individual level for further personalized medicine research. We proposed a straightforward method to determine the differential expression of each miRNA in an individual patient by utilizing the reversal expression order of miRNA pairs between two conditions (cancer and normal tissue). We applied our method to breast cancer miRNA expression profiles from The Cancer Genome Atlas and two other independent data sets. In total, 292 miRNAs were differentially expressed in individual breast cancer patients. Using the differential expression profile of miRNAs in individual patients, we found that the deregulations of miRNA tend to occur in specific breast cancer subtypes. We investigated the coordination effect between the miRNA and its target, based on the hypothesis that one gene function can be changed by copy number alterations of the corresponding gene or deregulation of the miRNA. We revealed that patients exhibiting an upregulation of hsa-miR-92b and patients with deletions of PTEN did not tend to overlap, and hsa-miR-92b and PTEN coordinately regulated the pathway of 'cell cycle' and so on. Moreover, we discovered a new prognostic signature, hsa-miR-29c, whose downregulation was associated with poor survival of breast cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.